There was a very rapid response [to CyBorD], which has been typical when you incorporate bortezomib into the initial regimens,” commented Dr. Anderson, from the Dana-Farber Cancer Institute in Boston.
There was a very rapid response [to CyBorD], which has been typical when you incorporate bortezomib into the initial regimens,” commented Dr. Anderson, from the Dana-Farber Cancer Institute in Boston.
“As is 100% of the time true, as far as I know, the adverse cytogenetics- del(13) and t(4;14)-are no longer relevant in the context of bortezomib- containing initial therapies.” The rate of complete or near-complete response increased from 39% to 46% to 72%, going from the intent-to-treat population to patients who completed treatment to transplant recipients, Dr. Anderson observed, characterizing the rates achieved as “truly remarkable.”
“I believe this is another example of a very active bortezomib-containing new therapy,” he said.
The main article can be found here:
CyBorD combo supports stem cell collection in newly diagnosed multiple myeloma
Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care
Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.